Novocure
Manufacturing · Switzerland · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
Neuhofstrasse 21, Baar, Zug, 6340, Switz...Phone Number
+44 1534756700Website
www.novocure.comRevenue
$699.2 MillionStock Symbol
NVCRIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Novocure
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer. Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, the company has offices in Germany, Switzerland, Japan and Israel.Explore more
Novocure Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Novocure your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Novocure recently announced quarterly report
Click to see if Novocure had a recent Job posting/layoffs
Check out if Novocure is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Novocure
Website visits: Recent activity has been detected on your website
Novocure, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Novocure has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Novocure has new funding data
Product Launch: Get notified when Novocure launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Novocure is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Novocure is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Novocure.
Novocure financials insights
Gather financial insights about Novocure, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Stock Offering
$158M
2018
Debt
$150M
2024
Debt
$400M
Novocure Tech Stack
A closer look at the technologies used by Novocure
See more technologies
Most Recent Scoops
Project
received CE mark approval for Optune Pax for the treatment of adult patients with locally advanced pancreatic cancer of exocrine origin, to be used concomitantly with gemcitabine and nab-paclitaxel, and has since finalized labeling and registration in Germany and begun certifying prescribers.
Project
reported that Optune Pax received 418 prescriptions during Q2 2026, with 285 patients on therapy as of June 30, reflecting successful early launch engagement with prescribers at both academic and community practices.
Pharmaceuticals
Project
Novocure announced that the KEYNOTE D58 phase III trial, exploring the addition of pembrolizumab to the standard of care of TTFields therapy and maintenance chemotherapy for GBM, is on track to complete enrollment by year-end 2026, with a database lock and top-line readout expected approximately two years thereafter.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Novocure has initiated several changes to the LUNAR-2 phase III trial, including reallocating clinical resources to high-enrollment sites, discontinuing the trial at lower-enrollment sites, and amending the protocol to streamline primary endpoints and reduce patient sample size, with these changes expected to cut total LUNAR trial spend by approximately $90 million, with savings allocated to pancreatic cancer programs.
Spending/Investment, Clinical Operations
Earnings
Earnings, Finance
Novocure News & Media
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NovoCure Limited - NVCR
NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited ("NovoCure" or the "Company") (NASDAQ: NVCR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The...HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026?
AI-powered diagnostics meet global oncology innovation as two medical disruptors post strong revenue growth, yet face distinct risk and valuation profiles.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Novocure
Sign Up For FreeTo access detailed company insights
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for... Read More
